The efficacy of oral adenosine A2A antagonist istradefylline for the treatment of moderate to severe Parkinson's disease

Ruxandra Julia Vorovenci, Angelo Antonini

Research output: Contribution to journalArticlepeer-review


The moderate and severe stages of Parkinson's disease (PD) are marked by motor and non-motor complications that still remain difficult to control with the currently available therapy. Adenosine A2A receptor antagonists target non-dopaminergic systems, and have emerged as promising add-on therapy in the management of PD, a little more than a decade ago. While the development of this new drug class was slower than initially expected, istradefylline was recently registered in Japan, because it provides reduction of the off-time, when given in association with levodopa. Effects on some non-motor features have also been suggested, and preliminary studies further suggest a potential neuroprotective effect. Associations of A2A receptor antagonists with dopaminergic agents, as well as enzyme blockers like catechol-O-methyltransferase (COMT) and monoamine oxidase-B (MAO-B) inhibitors, should provide even greater benefit in advanced PD patients, and, thus, a more individualized treatment approach would be at hand.

Original languageEnglish
Pages (from-to)1383-1390
Number of pages8
JournalExpert Review of Neurotherapeutics
Issue number12
Publication statusPublished - Dec 1 2015


  • A2A receptor antagonist
  • dyskinesia
  • istradefylline
  • levodopa add-on therapy
  • motor fluctuations
  • off time
  • Parkinson's disease
  • treatment

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'The efficacy of oral adenosine A<sub>2A</sub> antagonist istradefylline for the treatment of moderate to severe Parkinson's disease'. Together they form a unique fingerprint.

Cite this